Skip to main content
. 2018 Jun 25;132(10):1075–1084. doi: 10.1182/blood-2018-03-841932

Figure 2.

Figure 2.

ADMATS-13-preconditioning on TBI recovery and VWF reactivity. The modified Neurological Severity Scores (A; n = 33; 1-way ANOVA). (B) Kaplan-Meier survival plot of mice preconditioned with either rADAMTS-13 or PBS before FPI and sham mice (n = 33; P < .05 for FPI+rADAMTS-13 vs FPI+PBS, and for sham vs FPI+PBS, but not for FPI+rADAMTS-13 vs sham). Plasma VWF:Ag (C) and VWF:CB (D) of mice in the above groups (n = 33; 1-way ANOVA, *P < .01, **P < .001). (E) Plasma VWF-CB before (black bars) and after (white bars) adjustments for VWF:Ag (n = 18; paired t test, *P < .01, **P < .05). (F) PPP from mice receiving different treatments was probed for uncleaved (top) and cleaved (middle) VWF, using 2 specific antibodies. The bottom panel shows the densitometry ratio of cleaved to uncleaved VWF (n = 9, paired t test, *P < .01 and ** P < .05). (G) CD62 expression on platelets from mice of the above 3 treatment groups (n = 33, 1-way ANOVA, *P < .001).